VivoSeq
Oncology

Malignant Pleural Mesothelioma

85

Pipeline Programs↗

13

Active Trials↗

42

Companies Involved↗

Malignant Pleural Mesothelioma is a moderately active landscape with 85 programs across 42 companies. The most active players are Synta Pharmaceuticals Corp., Karuna Therapeutics, Inc., a Bristol Myers Squibb company, Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 1 therapy is approved with 16 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

68/100

Pipeline Velocity

0/100

Mech. Concentration

10/100

Completion Rate

75/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Synta Pharmaceuticals Corp.

1 program

Phase 1K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 1P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 1H

Hope Pharmaceuticals

1 program

Phase 1Roche logo

Roche

2 programs

Phase 2Pfizer logo

Pfizer

2 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

80%

Small molecule

60 of 75 classified programs — the dominant modality here.

20%ALL OTHERSMonoclonal antibody1115%Vaccine34%Protein / enzyme11%

Small molecule leads; the ring shows all 75 classified programs, each share of the total. Modality classified for 100% of 93 pipeline programs.

Analysis

Trial Status

87

clinical trials

Completed52 · 60%
Terminated12 · 14%
Recruiting6 · 7%
Active, not recruiting6 · 7%
Withdrawn5 · 6%
Unknown status5 · 6%
Other1 · 1%

Clinical Trials

Trial Activity

87 trials

Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced Malignant Pleural Mesothelioma
Recruiting·TTianjin Medical University Second Hospital·N/A·NCT06031636·15 enrolled
Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)
Recruiting·GGruppo Oncologico Italiano di Ricerca Clinica·Phase 3·NCT04996017·162 enrolled
First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma
Recruiting·—·Phase 2·NCT05188859·29 enrolled
Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma
Recruiting·HHyogo Medical University·Phase 2·NCT06318286·25 enrolled
Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma
Recruiting·UUniversity Hospital, Antwerp·Phase 1/2·NCT05765084·15 enrolled
Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)
Recruiting·—·Phase 1·NCT03760575·20 enrolled
Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients
Active, not recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT04287829·58 enrolled
Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma
Active, not recruiting·FFerring Ventures Limited·Phase 3·NCT03710876·53 enrolled
Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma
Active, not recruiting·—·Phase 2·NCT02153229·52 enrolled
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT03918252·30 enrolled
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
Active, not recruiting·National Cancer Institute (NCI)·Phase 1/2·NCT01064648·117 enrolled
Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00715611·65 enrolled
OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition
Not yet recruiting·OOncotelic Inc.·Phase 2·NCT05425576·63 enrolled
Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma
Completed·National Cancer Institute (NCI)·Phase 2·NCT00392444·39 enrolled
Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma
Completed·Eli Lilly logoEli Lilly·Phase 2·NCT00386815·20 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)